Abscisic acid (ABA), a plant stress hormone, has a chiral center (C1') in its molecule, yielding the
Compounds 3, 4 and 5 were prepared from Me ABA with NaBH 4 in THF described above. Oxidation of (1'S,2'S)-3 with PDC and subsequent alkaline hydrolysis produced (1'S,2'S)-(+)-2',3'-dihydro-ABA.
(1'R,2'R)-(-)-2',3'-dihydro-ABA was prepared from (-)-ABA by the same method as the (+)-enantiomer. (1'S,2'S)-(+)-2',3'-dihydro-4'-deoxo-ABA was synthesized described above. (1'S)-(+)-4'-deoxo-ABA was synthesized by elimination of the 4'-hydroxyl group of 5 with palladium-catalyzed borohydride reduction via the allylic carbonate before alkaline hydrolysis. The (-)-enantiomers of 2',3'-dihydro-4'-deoxo-ABA and 4'-deoxo-ABA were prepared by optical resolution of their racemates that were synthesized from (±)-ABA in the same manner as the (+)-enantiomer. The NMR and MS spectral data of these analogues are consistent with those reported previously. [27] [28] [29] Compared to the absolute configuration of the starting compound ABA, all the (+)-probes have the 1'S configuration, whereas all the (-)-probes have the 1'R configuration.
The favored conformation of the ring-modified probes was estimated to be a chair (half-chair in the case of 4'-deoxo-ABA) with the axial side chain on the basis of the NMR (NOE difference spectra and NOESY experiments) and theoretical analysis ( Figure 3 and Table 2 ). Therefore, we can discuss the effect of the local structural difference between these probes and ABA on the affinity for the enzyme active site.
The binding potency of (+)-and (−)-probes to the CYP707A3 active site
Both enantiomers of the probes were tested their ability to inhibit the 8'-hydroxylation reaction by recombinant CYP707A3, except for (+)-6-nor-ABA whose activity was reported previously. 19 The results are summarized in Table 1 . The mode of inhibition of all analogues with inhibition potency was competitive ( Figure 4A ,B). (-)-6-Nor-ABA did not inhibit the enzyme, unlike (+)-6-nor-ABA.
This suggests that the methyl group of the side chain has nothing to do with chiral recognition by CYP707A3. Therefore, the key moieties affecting the affinity for CYP707A3 should be the C4'-oxo, the C2',C3'-double bond, or both.
Each enone-modified (-)-probes exhibited a different affinity. The most active one was (1'R,2'R)-(-)-2',3'-dihydro-4'-deoxo-ABA with an K I value of 0.45 μM ( Table 1 ), indicating that this probe binds to the active site as effectively as (-)-AHI1. The structural difference of (-)-2',3'-dihydro-4'-deoxo-ABA from (-)-AHI1 is the existence of the side chain methyl (C6), suggesting that C6 in the (-)-enantiomer has little effect on binding to the active site, similarly to the (+)-enantiomer. (-)-2',3'-Dihydro-ABA exhibited no inhibitory activity, suggesting that the C4'-oxo moiety rather than the C2',C3'-double bond in (-)-ABA disturbs binding to the active site. (-)-4'-Deoxo-ABA functioned weakly as an inhibitor, although its activity was one-sixtieth that of (-)-2',3'-dihydro-4'-deoxo-ABA. This suggests that the presence of the C2',C3'-double bond also results in loss of affinity. Thus (-)-ABA cannot bind to the active site of CYP707A3 owing to the 4'-oxo moiety coupled with the C2',C3'-double bond.
All the enone-modified (+)-probes acted as weak inhibitors of CYP707A3. The absence of the ring enone in (+)-ABA results in a decrease affinity, although not necessarily significant.
A putative mechanism of asymmetrical ligand binding by CYP707A3
Biological chiral recognition toward a substrate with one stereocenter involves at least three locations interacting with one and more receptor sites. 30 ABA has three oxygenated functional groups: C1-carboxyl, C1'-hydroxyl, and C4'-oxo moiety. The C1-carboxyl in (+)-ABA is an absolutely essential moiety, including the (2Z,4E) geometry of the side chain, for binding to the CYP707A3 active site. 19 As described above, the C4'-oxo in (+)-ABA is also related to binding to the active site. On the other hand, the C1'-hydroxyl has nothing to do with binding to the active site. 19 Thus two of the three locations in (+)-ABA are the C1-carboxyl and C4'-oxo moieties, and the third location is not an oxygenated functional group. As shown in Figure 1B , the major difference between (+)-and (-)-ABA is the location of the axial C6'-methyl (C8') in the ring. Because C8' is the site hydroxylated by CYP707A3, it is reasonable to assume that C8' functions as a third location for the chiral recognition by CYP707A3. If the C1-and C4'-moieties of (-)-ABA interact with the active site similarly to (+)-ABA, the C8' of (-)-ABA cannot occupy the same location as that of (+)-ABA. However, the binding interaction is not required to occur in all three locations if the asymmetrical discrimination is not necessary. Simply, this may be the reason why (-)-AHI1 and (-)-2',3'-dihydro-4'-deoxo-ABA, which lacks the C4'-oxo function, can bind to the active site. These two probes may be mainly anchored to the active site through the C1-carboxyl, and reinforce the affinity by relatively non-specific, hydrophobic interactions by the lipophilic ring, although this binding manner should be different from that of (+)-ABA. In that case, (-)-ABA cannot bind to the active site in the similar manner to these probes, probably because the C4'-oxo moiety decreases the lipophilicity of the ring, or it has an unfavorable electrostatic interaction with the active site. This hypothesis led us to speculate that an ABA analogue with the same side chain as that of ABA, if its six-membered ring has no oxygenated functional group except for the C1'-hydroxyl group, can bind to the CYP707A3 active site, independent of its C1'-configuration. Therefore, we synthesized and tested the epimer of AHI1 (epi-AHI1). epi-AHI1 should adopt a chair conformation with the equatorial side chain because of the 1,3-diaxial repulsion between C7' and C8' ( Figure 5A and Table 2 ). Our previous study 19 suggests that ABA analogues with the C4'-oxo moiety are required to have the axial side chain in the favored conformation for a good affinity to the active site. Therefore, epi-AHI1 can be a good probe for testing our hypothesis about the binding mechanism of ABA analogues with no C4'-oxo moiety.
Synthesis of epi-AHI1
Racemic epi-AHI1 was prepared using the same synthetic route of AHI1 that was reported previously (
Figure 5B).
de-protected with AcOH and H 2 O, and oxidized with PDC to give the racemic aldehyde 7. The
Horner-Emmons reaction of 7 and subsequent alkaline hydrolysis gave epi-AHI1 with a total yield of 1.5%. The relative configurations of epi-AHI1 were determined on the basis of those of the compound 6. The introduction of the side chain to trimethylcyclohexanone yielded the compound 6 as the minor diastereomer. Because in this reaction the major diastereomer was the synthetic precursor of AHI1, the end product derived from the compound 6 must be the epimer of AHI1. Racemic epi-AHI1 was optically resolved to obtain (+)-and (-)-enantiomers using chiral HPLC, although the absolute configurations of optically pure epi-AHI1 have never been determined.
Both enantiomers of epi-AHI1 act as a substrate of CYP707A3
In the inhibition assay using recombinant CYP707A3, both enantiomers of epi-AHI1 competitively inhibited the enzyme reaction. The K I values for (+)-and (-)-epi-AHI1 were 2.50 μM and 1.63 μM, respectively (Table 1, Figure 4C ). This suggests that the affinity of both epi-AHI1 enantiomers for the enzyme active site is almost equivalent to that of AHI1 and 2',3'-dihydro-4'-deoxo-ABA. Each enantiomer of epi-AHI1 was converted into distinct UV-absorbing product during the enzyme reaction.
The product from (+)-epi-AHI1 showed a quasimolecular ion [M + Na] + at m/z 275 in the ESI-TOF-MS (positive mode) analysis; it has 14 additional mass unit compared to (+)-epi-AHI1. This suggests that a methylene group of epi-AHI1 was oxidized to a carbonyl group. Cytochrome P450s catalyze not only hydroxylation but also carbonylation and carboxylation. 26 In fact, P450-catalyzed oxidation of ABA includes the further oxidation of the first product 8'-hydroxy-ABA to 8'-oxo-ABA in maize cells. 31 Therefore, it is reasonable to assume that CYP707A3 catalyzes the two-step oxidation of epi-AHI1. On the other hand, the enzyme product of (-)-epi-AHI1 showed a quasimolecular ion at m/z 269 (positive mode), which cannot lead us to the estimated molecular structure.
In spite of its different conformation from that of AHI1 and other C4'-deoxo-probes prepared in this study, both enantiomers of epi-AHI1 occupied the active site of CYP707A3 to be converted to the enzyme reaction products. These results confirm our speculation that an ABA analogue with the same side chain as that of ABA, if its six-membered ring has no oxygenated functional group except for the C1'-hydroxyl group, can bind to the CYP707A3 active site, independent of its C1'-configuration. In the previous study, we developed AHI4 as a strong non-azole inhibitor of ABA 8'-hydroxylase. 21 The epimer of AHI4 at C2', epi-AHI4, adopts the similar ring conformation to epi-AHI1. Nevertheless, epi-AHI4 did not exhibit the enzyme inhibition activity. 21 epi-AHI4 has a hydroxyl group instead of the C8' of epi-AHI1; therefore, the ring of AHI4 should be more hydrophilic than that of AHI1. This may be the reason why epi-AHI4 did not act as an inhibitor of the enzyme.
Conclusions
Plant P450 CYP707A3, ABA 8'-hydroxylase, binds enantioselectively (+)-ABA but not (-)-ABA, whereas the enzyme binds both enantiomers of AHI1. We focused on the structural differences between the two compounds, and designed and synthesized four asymmetrical molecular probes for exploring a key functional group of (-)-ABA responsible for disturbing binding to the active site: 6-nor-ABA; 2',3'-dihydro-ABA; 4'-deoxo-ABA; and 2',3'-dihydro-4'-deoxo-ABA. The structure-activity studies using these probes suggested that the C4'-carbonyl moiety coupled with the C2',C3'-double bond is a significant key function for asymmetrical binding of ABA by ABA 8'-hydroxylase.
Experimental

Chemicals
(+)-ABA was a gift from Toray Industries Inc., Tokyo, Japan. Phaseic acid was prepared as reported previously. 32 Synthesis of (±)-AHI1 was reported previously. For clarity, the atoms of all the compounds with the carbon skeleton of ABA were numbered as in ABA for peak assignments. High resolution mass spectra (HRMS) were obtained with a JEOL JMS-DX 303 HF mass spectrometer and with a JEOL JMS-T100LC "AccuTOF". Optical rotation was recorded with a Jasco DIP-1000 digital polarimeter. Column chromatography was performed on silica gel (Wakogel C-200). Purity in two solvent systems (H 2 O-MeOH and H 2 O-MeCN) was determined using a Shimadzu LC-10ADVP instrument, and all final compounds were >97% pure (see Supporting Information for details).
(+)-and (-)-AHI1
(±)-AHI1 20 (45 mg, 0.19 mmol) were subjected to chiral HPLC under the following conditions: column, added to the solution at 0 °C, and the resulting mixture was stirred for 105 min at room temperature in the dark. After quenching the reaction with brine, the CH 2 Cl 2 layer was separated, and the aqueous layer was extracted with EtOAc (10 mL × 5). The CH 2 Cl 2 and EtOAc layers were combined, washed with saturated NaHCO 3 , 0.1 M HCl, brine and H 2 O, dried over Na 2 SO 4 , and concentrated. The residual oil was purified by column chromatography on silica gel with 5% EtOAc in hexane to give the thiono ester (0.21 g) as yellow oil. The thiono ester (0.11 g) was dissolved in dry toluene (3 mL) and warmed to 70 °C. A solution of 2,2'-azobisisobutyronitrile (7.3 mg, 45 μmol) and tri-n-butyltin hydride (0.2 mL, 0.76 mmol) in toluene (1.5 mL) was added dropwise to the solution over 3 min, and the resulting mixture was stirred for 2 h at 70 °C under Ar. The toluene solution was applied onto silica gel column and products were eluted with 8% EtOAc in hexane. The eluate was concentrated, the residue (34 mg) was redissolved in MeOH (1.5 mL), and 1 M NaOH (1.5 mL, 1.5 mmol) was added to the solution. After stirring for 16.5 h, the solution was filled up to 50 mL with brine. The resulting solution was extracted with hexane (5 mL × 3), and the aqueous layer was extracted with EtOAc (8 mL 2-propanol in n-hexane containing 0.1% TFA; flow rate, 1.0 ml min -1 ; detection, 254 nm. The peaks at t R 6.7 and 7.5 min were detected when the (±)-2 was injected, whereas the peak from injected 2 was detected at t R 6.5 min. 
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. A solution of sodium bis(2-methoxyethoxy)aluminum dihydride (SMEAH) in toluene (ca 70%, 0.85 mL, 3.1 mmol) was added dropwise to a solution of 6 (0.27 g, 0.88 mmol) in dry THF (25 mL) at 0 °C under Ar.
The mixture was stirred for 2 h at room temperature before it was poured into H 2 O. The solution was extracted with EtOAc (20 mL × 8) after saturated NaHCO 3 was added to the solution. The organic layer was washed with saturated NH 4 Cl and H 2 O, dried over Na 2 SO 4 and concentrated. After the residual oil (0.24 g) was dissolved in THF (1 mL), 75% AcOH in H 2 O (4 mL) was added to the solution, and the mixture was then stirred for 19 h at room temperature. The resulting mixture was filled up with brine to 40 mL before being extracted with EtOAc (7 mL × 8). The organic layer was washed substantially with saturated NaHCO 3 and H 2 O, dried over Na 2 SO 4 and concentrated. The residual oil was purified by column chromatography on silica gel with 30% EtOAc in hexane to give 
